PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Emmanuel Nwangele

Université Laval

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models

Clinical Cancer Research

Sound preclinical efficacy in multiple xenograft models with dose-dependent activity and acceptable safety, but limited to in vivo animal studies without human data.

PromisingEmmanuel Nwangele Humphrey Fonge Hanan Babeker

Reported

Complete remission rate (SW1990 C…16.7%

Durable tumor growth suppression…83.3%

Durable tumor growth suppression…≥50 days

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support